GLP-1 'Microdosing': What the Trend Claims, and Why It's Largely Unverified
Microdosing GLP-1 drugs — taking doses below the labeled starting dose — has spread on social media. Here's what's actually been studied.
By the GLP Semaglutide editorial team · Last updated September 18, 2025
'Microdosing' GLP-1 drugs generally refers to taking doses smaller than the labeled starting dose, often using compounded products that allow finer dose adjustment than prefilled brand-name pens.
What's actually behind the claims
Most microdosing claims circulating online are anecdotal rather than backed by published clinical trial data at those specific sub-label doses. FDA-approved labeling doesn't include a microdosing regimen for any GLP-1 drug.
The sourcing problem compounds the risk
Microdosing protocols are often paired with compounded products obtained outside standard pharmacy channels, which layers an unverified dosing approach on top of an unverified product-sourcing question. Anyone considering this should raise it directly with a licensed prescriber rather than follow social-media protocols.
Primary sources